A carregar...
Improved targeting of an anti‐TAG‐72 antibody drug conjugate for the treatment of ovarian cancer
INTRODUCTION: Ovarian cancer has only a 17% 5‐year survival rate in patients diagnosed with late stage disease. Tumor‐associated glycoprotein‐72 (TAG72), expressed in 88% of all stages of ovarian cancer, is an excellent candidate for antibody‐targeted therapy, as it is not expressed in normal human...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7333846/ https://ncbi.nlm.nih.gov/pubmed/32368864 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3078 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|